ASH Conference Coverage

New Data for DARZALEX® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma

(Janssen) Dec 11, 2017 - Early data evaluated subcutaneous delivery of DARZALEX in relapsed or refractory multiple myeloma (oral presentation; Abstract #838); new Phase 2 data investigated single-agent DARZALEX for intermediate or high-risk smoldering multiple myeloma (oral presentation; Abstract #510).

read corporate press release

DARZALEX® (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible

(Janssen) Dec 12, 2017 - Phase 3 ALCYONE data showed DARZALEX in combination with bortezomib, melphalan and prednisone meaningfully improved progression-free survival and response rates; data featured as late-breaker at ASH 2017 (Abstract #LBA-4) and published in the New England Journal of Medicine.

read corporate press release

Late-Breaking Clinical Trials Signal New Therapeutic Options for Many Patients in the Near Term

(ASH 2017) Dec 12, 2017 - In four clinical trials being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report promising results suggesting patients with blood disorders and several types of cancer will soon have significantly expanded options for treatment.

read press release

Chemotherapy-Free Cancer Treatments Move Closer To Reality

(Forbes) Dec 12, 2017 - CAR T-cell treatments continue to achieve impressive results in treating an ever-increasing variety of cancers, but will they ever be able to completely replace chemotherapy?

read article

Genentech Announces Phase III Data Showing Venclexta plus Rituxan Reduced the Risk of Disease Progression or Death by 83 Percent Compared to a Standard of Care Regimen in Previously Treated Chronic Lymphocytic Leukemia

(Genentech) Dec 12, 2017 - Genentech, a member of the Roche Group, today announced the first results from the pivotal Phase III MURANO study evaluating Venclexta™ (venetoclax) plus Rituxan® (rituximab) compared to bendamustine plus Rituxan (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukemia (CLL).

read corporate press release

Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017

(Kyowa Kirin) Dec 11, 2017 - Kyowa Hakko Kirin Co., Ltd. announced today that the results of the Global Phase 3 study (MAVORIC: Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) investigating the use of mogamulizumab (KW-0761) in patients with cutaneous T-cell lymphoma (CTCL) will be presented at the Annual Meeting of American Society of Hematology 2017.

read corporate press release

KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial

(Amgen) Dec 11, 2017 - Amgen today announced new results showing the positive overall survival (OS) findings from the final analysis of Phase 3 ASPIRE trial.

read corporate press release

Ablynx Reports Additional Clinically Important Benefits Of Caplacizumab From Its Phase III HERCULES Study In Acquired TTP

(Ablynx) Dec 12, 2017 - Ablynx NV today announced additional results from the Phase III HERCULES study with caplacizumab, the Company's anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).

read corporate press release

Once-Daily, Oral SAVAYSA® (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study

(Business Insider) Dec 12, 2017 - Daiichi Sankyo, Inc., today announced results from the Hokusai-VTE CANCER study evaluating oral edoxaban (known by the brand names SAVAYSA® in the U.S. and LIXIANA® outside the U.S.), and found that edoxaban is non-inferior to subcutaneous injectable LMWH dalteparin for the treatment of cancer-associated VTE or major bleeding.

read article

Celgene CEO: New Therapies For A Certain Type Of Cancer Boost Survival Rates 10-Fold

(CNBC) Dec 11, 2017 - A new approach to treating patients suffering from an aggressive form of blood cancer could increase survival rates 10-fold to 20 years, Celgene CEO Mark Alles told CNBC on Monday.

read article

Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented

(NASDAQ) Dec 13, 2017 - Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, presented detailed data from its SL-401 pivotal trial in BPDCN, as well as results from other ongoing trials in additional indications, at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held in Atlanta, GA.

read article

BioSight Announces Phase I/II Results of its Cytarabine Pro-Drug BST-236 for Treatment of Acute Leukemia

(Morningstar) Dec 14, 2017 - BioSight Ltd, a pharmaceutical development company, focused on the development of targeted oncology drugs, reports positive final results in a Phase I/II multi-center, open label, dose-escalating study of its lead product BST-236, a novel cytarabine pro-drug, as a single agent for induction therapy in acute leukemia patients.

read article

ASH 2017 – Transcend Fails To Prevent Juno’s Second Collapse

(EP Vantage) Dec 12, 2017 - Juno had hoped that the Ash meeting would mark its return as a competitive force in CAR-T. Instead, a keenly awaited update of its now pivotal lymphoma trial, Transcend, disappointed, and yesterday’s 14% share price collapse marked the second year in a row that Ash left the company nursing heavy losses.

read article

Advances in Multiple Myeloma, Lymphoma, and Histiocytosis among Results Presented at 2017 ASH Meeting

(MSK/OnCancer Blog) Dec 12, 2017 - At the 2017 meeting, held December 9 to 12 in Atlanta, Memorial Sloan Kettering researchers reported important progress in the treatment of several blood cancers.

read article

Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials

(Markets Insider) Dec 12, 2017 - Servier, Pfizer Inc. and Cellectis presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta preliminary results from two phase 1 studies of UCART19, an investigational allogeneic anti-CD19 CAR T-cell product, in adult and pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (B-ALL). These first-in-human data demonstrated the safety and tolerability of UCART19, resulting in an 83% complete remission rate across the adult and pediatric patient population.

read article

Study Shows Survival Benefits For Seeing An NCI Specialist For Multiple Myeloma

(UNC Lineberger) Dec 12, 2017 - Patients with multiple myeloma who saw a specialist at a National Cancer Institute-designated comprehensive Cancer Center had better overall survival than patients who only saw a community oncologist, according to a study from the University of North Carolina Lineberger Comprehensive Cancer Center.

read article

Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH)

(Yahoo! Finance) Dec 13, 2017 - Spectrum Pharmaceuticals announced two oral presentations of data on FOLOTYN and research progress for the treatment of Peripheral T-Cell Lymphoma (PTCL) at the 59th American Society of Hematology (ASH).

read article

Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH

(Markets Insider) Dec 12, 2017 - Juno Therapeutics, Inc., a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today highlighted presentations and data from the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia, December 9-12, 2017.

read article

Interdisciplinary Teams Can Help Decrease Hospital Readmissions

(CureToday.com) Dec 13, 2017 - Hospital readmissions soon after discharge can be costly and detrimental to patient care, but according to a recent study conducted at the Cleveland Clinic and presented at the 2017 American Society of Hematology’s Annual Meeting and Exposition, creating an interdisciplinary team to work with patients can help.

read article

New Southampton Study Could Help Tailor Treatment For Most Common Type Of Leukaemia

(University of Southampton [UK]) Dec 19, 2017 - New findings by scientists at the University of Southampton could help to predict how people with the most common form of leukaemia will respond to chemotherapy. The findings will help doctors decide which type of treatment to give patients.

read article
Next Page